Technical Analysis for CNCR - Loncar Cancer Immunotherapy ETF

Grade Last Price % Change Price Change
grade D 20.305 0.33% 0.07
CNCR closed up 0.33 percent on Friday, September 20, 2019, on 88 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Flat Up
See historical CNCR trend table...

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
MACD Bullish Centerline Cross Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Overbought Stochastic Strength 0.00%
Stochastic Sell Signal Bearish 1.83%
Multiple of Ten Bearish Other 1.83%
Weak + Overbought Other 1.83%
Overbought Stochastic Strength 1.83%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.82%

Older signals for CNCR ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
ETF Series Solutions - Loncar Cancer Immunotherapy ETF is an exchange traded fund launched by ETF Series Solutions. The fund is co-managed by Exchange Traded Concepts, LLC and Vident Investment Advisory, LLC. It invests in public equity markets of the United States. The fund invests in stocks of companies operating in the pharmaceutical or biotechnology sectors, including those companies identified as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. It invests in stocks of companies across all market capitalizations. The fund seeks to replicate the performance of the Loncar Cancer Immunotherapy Index, by investing in stocks of companies as per their weightings in the index. ETF Series Solutions - Loncar Cancer Immunotherapy ETF is domiciled in the United States.
Exchange Traded Funds Biotechnology Cancer Betashares SPDR Biotechnology Sectors Loncar Cancer Immunotherapy Index
Is CNCR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 25.08
52 Week Low 16.87
Average Volume 5,578
200-Day Moving Average 20.5524
50-Day Moving Average 20.2714
20-Day Moving Average 19.6434
10-Day Moving Average 19.9218
Average True Range 0.3187
ADX 16.12
+DI 26.1101
-DI 25.7714
Chandelier Exit (Long, 3 ATRs ) 19.4547
Chandelier Exit (Short, 3 ATRs ) 19.9471
Upper Bollinger Band 20.398
Lower Bollinger Band 18.8888
Percent B (%b) 0.94
BandWidth 7.682988
MACD Line 0.0217
MACD Signal Line -0.1058
MACD Histogram 0.1276
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 20.50
Resistance 3 (R3) 20.48 20.40 20.47
Resistance 2 (R2) 20.40 20.35 20.41 20.46
Resistance 1 (R1) 20.35 20.32 20.37 20.37 20.45
Pivot Point 20.27 20.27 20.28 20.28 20.27
Support 1 (S1) 20.22 20.22 20.24 20.24 20.16
Support 2 (S2) 20.13 20.18 20.14 20.15
Support 3 (S3) 20.09 20.13 20.14
Support 4 (S4) 20.11